دورية أكاديمية
أعرض في EDS

The Topical Novel Formulations of Interferon α-2в Effectively Inhibit HSV-1 Keratitis in the Rabbit Eye Model and HSV-2 Genital Herpes in Mice.

التفاصيل البيبلوغرافية
العنوان: The Topical Novel Formulations of Interferon α-2в Effectively Inhibit HSV-1 Keratitis in the Rabbit Eye Model and HSV-2 Genital Herpes in Mice.
المؤلفون: Ivanina A; Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia., Leneva I; Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia., Falynskova I; Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia., Glubokova E; Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia., Kartashova N; Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia., Pankova N; OOO Firn M, Biotech Company, 108804 Moscow, Russia., Korovkin S; OOO Firn M, Biotech Company, 108804 Moscow, Russia., Svitich O; Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia.
المصدر: Viruses [Viruses] 2024 Jun 19; Vol. 16 (6). Date of Electronic Publication: 2024 Jun 19.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مواضيع طبية MeSH: Herpesvirus 1, Human*/drug effects , Herpesvirus 2, Human*/drug effects , Antiviral Agents*/administration & dosage , Antiviral Agents*/pharmacology , Antiviral Agents*/therapeutic use , Herpes Genitalis*/drug therapy , Herpes Genitalis*/virology , Disease Models, Animal* , Keratitis, Herpetic*/drug therapy , Keratitis, Herpetic*/virology, Animals ; Rabbits ; Mice ; Chlorocebus aethiops ; Female ; Vero Cells ; Interferon alpha-2/administration & dosage ; Interferon alpha-2/therapeutic use ; Virus Replication/drug effects ; Administration, Topical ; Ophthalmic Solutions ; Interferon-alpha/administration & dosage ; Humans
مستخلص: Herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) are widespread human pathogens that establish chronic latent infections leading to recurrent episodes. Current treatments are limited, necessitating the development of novel antiviral strategies. This study aimed to assess the antiviral efficacy of novel topical formulations containing interferon alpha-2b (IFN α-2b) against HSV-1 and HSV-2. The formulations, Oftalmoferon ® forte (eye drops) and Interferon Vaginal Tablets, demonstrated potent antiviral effects against HSV-1 and HSV-2 in Vero cells, respectively, with concentration-dependent inhibition of viral replication. Subsequently, their efficacy was tested in animal models: HSV-1 keratitis in the rabbit eye model and HSV-2 genital herpes in mice. Oftalmoferon ® forte effectively treated HSV-1 keratitis, reducing clinical symptoms and ulcerations compared to virus control. Interferon Vaginal Tablets showed promising results in controlling HSV-2 genital herpes in mice, improving survival rates, reducing clinical signs, weight loss and viral replication. The novel IFN α-2b formulations exhibited significant antiviral activity against HSV infections in cell culture and animal models. These findings suggest the potential of these formulations as alternative treatments for HSV infections, particularly in cases resistant to current therapies. Further studies are warranted to optimize treatment regimens and assess clinical efficacy in humans.
References: AIDS. 2001 Aug;15 Suppl 4:S97-108. (PMID: 11686471)
Herpes. 2004 Jun;11 Suppl 2:57A-64A. (PMID: 15319091)
Ann Intern Med. 1983 Jun;98(6):973-83. (PMID: 6344713)
Front Cell Infect Microbiol. 2021 Jan 18;10:617578. (PMID: 33537244)
Antimicrob Agents Chemother. 2020 Aug 20;64(9):. (PMID: 32601167)
Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2529-34. (PMID: 12766053)
Nurs Clin North Am. 2020 Sep;55(3):337-345. (PMID: 32762854)
Semin Immunol. 2019 Jun;43:101300. (PMID: 31771760)
Pediatr Infect Dis J. 1994 Feb;13(2):170. (PMID: 8190555)
J Virol. 2016 May 27;90(12):5534-5537. (PMID: 27053547)
In Vivo. 1998 Sep-Oct;12(5):481-4. (PMID: 9827354)
Pathogens. 2023 Jul 19;12(7):. (PMID: 37513800)
Curr Med Res Opin. 2007 Oct;23(10):2441-52. (PMID: 17723160)
J Clin Invest. 2020 Jul 1;130(7):3361-3369. (PMID: 32364538)
Sex Transm Dis. 2001 Apr;28(4):187-94. (PMID: 11318248)
Surv Ophthalmol. 2012 Sep;57(5):448-62. (PMID: 22542912)
J Immunol. 1997 Sep 15;159(6):2932-40. (PMID: 9300717)
Cell Microbiol. 2004 May;6(5):401-10. (PMID: 15056211)
Antiviral Res. 2006 Sep;71(2-3):141-8. (PMID: 16675036)
J Allergy Clin Immunol. 1989 Apr;83(4):771-6. (PMID: 2540229)
Virulence. 2021 Dec;12(1):2670-2702. (PMID: 34676800)
Geburtshilfe Frauenheilkd. 2016 Dec;76(12):1310-1317. (PMID: 28017972)
Invest Ophthalmol. 1973 May;12(5):378-80. (PMID: 4196692)
J Infect Dis. 2002 Apr 15;185(8):1019-24. (PMID: 11930310)
JAMA. 1982 Sep 3;248(9):1041-9. (PMID: 7109193)
Antibiot Khimioter. 2009;54(5-6):54-6, 58. (PMID: 20052919)
Immunol Rev. 2013 Sep;255(1):25-39. (PMID: 23947345)
Ter Arkh. 2016;88(11):76-82. (PMID: 28005035)
Clin Exp Ophthalmol. 2018 Dec;46(9):1008-1016. (PMID: 29749113)
Cornea. 2001 Jan;20(1):1-13. (PMID: 11188989)
Ann Allergy Asthma Immunol. 1996 May;76(5):469-75. (PMID: 8630722)
Sex Transm Dis. 2001 Jan;28(1):47-50. (PMID: 11196047)
Int J Oral Sci. 2016 Mar 30;8(1):1-6. (PMID: 27025259)
فهرسة مساهمة: Keywords: HSV-1; HSV-2; genital herpes infection; herpetic stromal keratitis; interferon alpha-2b; topical formulations
المشرفين على المادة: 0 (Antiviral Agents)
0 (Interferon alpha-2)
0 (Ophthalmic Solutions)
0 (Interferon-alpha)
تواريخ الأحداث: Date Created: 20240627 Date Completed: 20240627 Latest Revision: 20240705
رمز التحديث: 20240705
مُعرف محوري في PubMed: PMC11209562
DOI: 10.3390/v16060989
PMID: 38932280
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4915
DOI:10.3390/v16060989